Hepatitis C infection increases risk for developing kidney cancer

Physicians at Henry Ford Hospital have found that infection with the hepatitis C virus increases the risk for developing kidney cancer.

Using administrative data from more than 67,000 Henry Ford Health System patients, physicians found that over the period 1997-2008, 0.6% (17/3057) patients with hepatitis C infection developed kidney cancer whereas only 0.3% (17/64006) patients without the disease developed kidney cancer.

After controlling for age, gender, race and underlying kidney disease, hepatitis C infected patients had nearly double the risk of developing kidney cancer.

"These results add to growing literature that shows that the hepatitis C virus causes disease that extends beyond the liver, and in fact most of our HCV-infected kidney cancer patients had only minimal liver damage," says Stuart C. Gordon, M.D., director of Hepatology at Henry Ford Hospital and lead author of the study.

The study was published in this month's Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Dr. Gordon explains that the results suggest a more careful surveillance of newly diagnosed kidney cancer patients for the presence of hepatitis C infection, one of the few cancers with a rising global incidence. He adds that it is premature to recommend more comprehensive screening of HCV-positive patients.

"However, a heightened awareness of an increased kidney cancer risk should dictate more careful follow-up of incidental renal defects when detected on imaging procedures in patients with chronic hepatitis C," says Dr. Gordon.

The researchers also found that the average age of HCV-positive patients with kidney cancer was significantly younger than those HCV-negative patients with kidney cancer, a cancer that generally affects older individuals.

Dr. Gordon explains that hepatitis C is curable in more than 50 percent of cases and that newer and better treatment regimens are being developed. Henry Ford Hospital is participating in a number of these trials.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New therapeutic target overcomes ovarian cancer immunotherapy resistance